1,222 research outputs found
Proteinase inhibitor therapy of severe inflammation in pigs: First results with eglin, a potent inhibitor of granulocyte elastase and cathepsin G.
Monte Carlo aided design of the inner muon veto detectors for the Double Chooz experiment
The Double Chooz neutrino experiment aims to measure the last unknown
neutrino mixing angle theta_13 using two identical detectors positioned at
sites both near and far from the reactor cores of the Chooz nuclear power
plant. To suppress correlated background induced by cosmic muons in the
detectors, they are protected by veto detector systems. One of these systems is
the inner muon veto. It is an active liquid scintillator based detector and
instrumented with encapsulated photomultiplier tubes. In this paper we describe
the Monte Carlo aided design process of the inner muon veto, that resulted in a
detector configuration with 78 PMTs yielding an efficiency of 99.978 +- 0.004%
for rejecting muon events and an efficiency of >98.98% for rejecting correlated
events induced by muons. A veto detector of this design is currently used at
the far detector site and will be built and incorporated as the muon
identification system at the near site of the Double Chooz experiment
GranulozytĂ€re Elastase als Marker der unspezifischen Proteolyse in der Pathogenese entzĂŒndlicher Erkrankungen
Influence of the lysosomal elastase inhibitor eglin on development of interstitial lung edema in E. coli bacteremia in pigs
Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in open-heart surgery
Intraoperative administration of the proteinase Inhibitor aprotinin causes reduction in blood loss and homologous blood requirement in patients undergoing cardiac surgery. To ascertain the blood-saving effect of aprotinin and to obtain further information about the mode of action, 40 patients undergoing primary myocardial revascularization were randomly assigned to receive either aprotinin or placebo treatment. Aprotinin was given as a bolus of 2 X 105 kallikrein inactivator units (KIU) before surgery followed by a continuous infusion of 5 X 105 KIU/h during surgery. Additionally, 2 X 105 KIU were added to the pump prime. Strict criteria were used to obtain a homogeneous patient selection. Total blood loss was reduced from 1,431 +/- 760 ml in the control group to 738 +/- 411 ml in the aprotinin group (P < 0.05) and the homologous blood requirement from 838 +/- 963 ml to 163 +/- 308 ml (P < 0.05). In the control group, 2.3 +/- 2.2 U of homologous blood or blood products were given, and in the aprotinin group, 0.63 +/- 0.96 U were given (P < 0.05). Twenty-five percent of patients in the control group and 63% in the aprotinin group did not receive banked blood or homologous blood products. The activated clotting time as an indicator of inhibition of the contact phase of coagulation was significantly Increased before heparinization in the aprotinin group (141 +/- 13 s vs. 122 +/- 25 s) and remained significantly Increased until heparin was neutralized after cardiopulmonary bypass (CPB). The concentration of the thrombin-antithrombin III complex was significantly decreased at the end of CPB in the aprotinin group, indicating less thrombin generation in the aprotinin-treated group. The total concentration of the fibrinogen-fibrin split products (FSP) and the split products of the cross-linked fibrin (D-dimers) were also significantly reduced due to attenuated proteolytic activities of thrombin and plasmin. The results of the fibrin plate assay revealed higher fibrinolytic activity during CPB in the control group. The results demonstrate the beneficial effect of high-dose aprotinin treatment on blood loss and homologous blood requirement. This effect can be attributed to the inhibition of the contact phase of coagulation and the consequently reduced thrombotic and fibrionolytic activity during and after CPB
- âŠ